Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cytori Diagnostics Reports Preliminary 2008 Results
Celution System and StemSource product sales accounted for $4.5 million of the total. The company anticipates 2009 product revenues of at least $10 million. Product revenue in 2009
Celution System and StemSource product sales accounted for $4.5 million of the total. The company anticipates 2009 product revenues of at least $10 million. Product revenue in 2009
Net income in 2008 was $68.4 million, or $0.47 per diluted share, compared to a net loss of $21.1 million, or $0.08 per diluted share, in 2007. Total
As vice president of business-to-business and Puerto Rico, Mr Azar will oversee the company’s public payer, managed care and wholesaler operations in the US as well as oversee
The biologics license application (BLA) submission is based on data from a total of 1,082 treated Dupuytren’s contracture patients and over 2,600 injections of Xiaflex. Auxilium has requested
Mr Wilke will report directly to Raymond Merk, Datatrak’s CFO and COO, and be integrally involved in the development of the Datatrak eClinical platform. The company also announced
Chemaphor said that it has core expertise in organic chemistry and as a secondary activity, specializes in the synthesis of research chemicals labeled with stable isotopes. The use
Dr Yocum will be responsible for leading the clinical development of soluble ferric pyrophosphate (SFP), the company’s proprietary iron maintenance product currently progressing through a US Phase II
Managed Health Services (MHS), a Medicaid managed care company, serving SCHIP and Hoosier Healthwise members in Indiana engaged SynCare to assist the company in providing comprehensive care and
In collaboration with Avid Radiopharmaceuticals, ProteoTech scientists will utilize ProteoTech’s small molecule platform drug technology to develop new imaging agents that will allow doctors to use PET imaging
ASP2314/ACR-16 represents a novel class for the treatment of schizophrenia and other CNS disorders. In 2005, Astellas obtained rights from Carlsson Research (current Neurosearch) to develop, manufacture and